Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRN NASDAQ:MGEN NASDAQ:OPGN NASDAQ:SNWV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$15.01+0.3%$15.48$7.08▼$17.49$309.62M0.7752,947 shs45,523 shsMGENMiragen Therapeutics$19.65-0.9%$17.69$4.66▼$34.05$76.79M1.66134,027 shs467,267 shsOPGNOpGen$2.58$0.00▼$0.00$1K-1.77596 shs21 shsSNWVSanuwave Health$36.98-0.1%$37.89$5.63▼$46.58$317.19M1.3939,591 shs29,349 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin-0.13%-0.40%+0.47%+12.98%+27.32%MGENMiragen Therapeutics-1.93%+1.80%+17.35%+26.48%+0.10%OPGNOpGen0.00%0.00%0.00%-100.00%-100.00%SNWVSanuwave Health+5.26%-4.19%-11.22%+24.65%+3,701,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$15.01+0.3%$15.48$7.08▼$17.49$309.62M0.7752,947 shs45,523 shsMGENMiragen Therapeutics$19.65-0.9%$17.69$4.66▼$34.05$76.79M1.66134,027 shs467,267 shsOPGNOpGen$2.58$0.00▼$0.00$1K-1.77596 shs21 shsSNWVSanuwave Health$36.98-0.1%$37.89$5.63▼$46.58$317.19M1.3939,591 shs29,349 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin-0.13%-0.40%+0.47%+12.98%+27.32%MGENMiragen Therapeutics-1.93%+1.80%+17.35%+26.48%+0.10%OPGNOpGen0.00%0.00%0.00%-100.00%-100.00%SNWVSanuwave Health+5.26%-4.19%-11.22%+24.65%+3,701,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 1.50Reduce$12.00-20.05% DownsideMGENMiragen Therapeutics 0.00N/AN/AN/AOPGNOpGen 0.00N/AN/AN/ASNWVSanuwave Health 3.33Buy$55.0048.73% UpsideCurrent Analyst Ratings BreakdownLatest MGEN, OPGN, AMRN, and SNWV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025SNWVSanuwave HealthNorthland CapmkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/3/2025SNWVSanuwave HealthNorthland SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$55.008/25/2025AMRNAmarinZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/22/2025SNWVSanuwave HealthRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$54.00 ➝ $55.007/29/2025SNWVSanuwave HealthRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$49.006/25/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$7.00 ➝ $12.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$228.61M1.36N/AN/A$23.62 per share0.64MGENMiragen Therapeutics$4.46M17.22N/AN/A$6.78 per share2.90OPGNOpGen$2.67M0.00N/AN/A($11.55) per share0.00SNWVSanuwave Health$32.63M9.71N/AN/A($1.49) per share-24.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$82.18M-$3.67N/AN/AN/A-47.22%-21.18%-15.00%10/29/2025 (Estimated)MGENMiragen Therapeutics-$41.87M-$20.09N/AN/AN/A-1,393.50%-141.66%-88.74%N/AOPGNOpGen-$32.67MN/A0.00N/AN/A-1,140.36%N/A-287.58%11/13/2025 (Estimated)SNWVSanuwave Health-$31.37M-$8.25N/A∞N/A-97.03%N/A-135.15%N/ALatest MGEN, OPGN, AMRN, and SNWV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025SNWVSanuwave Health-$0.09$0.01+$0.10$0.01$10.14 million$10.16 million7/30/2025Q2 2025AMRNAmarin-$0.66-$0.03+$0.63-$0.03$45.45 million$72.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/AMGENMiragen TherapeuticsN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/ASNWVSanuwave HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.262.34MGENMiragen Therapeutics0.204.234.23OPGNOpGenN/A5.455.45SNWVSanuwave HealthN/A0.430.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%MGENMiragen TherapeuticsN/AOPGNOpGen2.68%SNWVSanuwave Health42.53%Insider OwnershipCompanyInsider OwnershipAMRNAmarin3.30%MGENMiragen Therapeutics1.10%OPGNOpGen43.80%SNWVSanuwave Health14.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.68 million20.00 millionOptionableMGENMiragen Therapeutics453.91 millionN/ANot OptionableOPGNOpGen10010.07 million4.70 millionNot OptionableSNWVSanuwave Health408.57 million7.29 millionN/AMGEN, OPGN, AMRN, and SNWV HeadlinesRecent News About These CompaniesSanuwave Health (NASDAQ:SNWV) Downgraded to Buy Rating by Wall Street ZenSeptember 9 at 3:29 AM | marketbeat.comSanuwave Health (NASDAQ:SNWV) Stock Rating Lowered by Wall Street ZenSeptember 9 at 3:29 AM | marketbeat.comSanuwave Health (NASDAQ:SNWV) Downgraded to "Buy" Rating by Wall Street ZenSeptember 8, 2025 | americanbankingnews.comNorthland Capmk Forecasts Sanuwave Health Q3 EarningsSeptember 7, 2025 | marketbeat.comSanuwave Health (NASDAQ:SNWV) Upgraded to "Strong-Buy" at Northland CapmkSeptember 6, 2025 | marketbeat.comSanuwave Health (NASDAQ:SNWV) Upgraded by Northland Capmk to Strong-Buy RatingSeptember 6, 2025 | americanbankingnews.comSanuwave Health (NASDAQ:SNWV) Earns Outperform Rating from Analysts at Northland SecuritiesSeptember 6, 2025 | americanbankingnews.comNorthland Capmk Predicts Sanuwave Health Q3 EarningsSeptember 6, 2025 | americanbankingnews.comSanuwave Health (NASDAQ:SNWV) Now Covered by Northland SecuritiesSeptember 5, 2025 | marketbeat.comAWM Investment Company Inc. Invests $18.15 Million in Sanuwave Health Inc. $SNWVSeptember 5, 2025 | marketbeat.comSolas Capital Management LLC Invests $20.66 Million in Sanuwave Health Inc. $SNWVSeptember 2, 2025 | marketbeat.comSanuwave Health (NASDAQ:SNWV) Rating Increased to Strong-Buy at Wall Street ZenSeptember 1, 2025 | marketbeat.comSANUWAVE Health, Inc. (SNWV) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comSanuwave (SNWV) Q2 Revenue Jumps 42%August 8, 2025 | fool.comSanuwave Announces Q2 FY2025 Financial ResultsAugust 8, 2025 | globenewswire.comSanuwave Will Host a Conference Call on August 8, 2025 at 8:30 AM (ET) to Present Q2 2025 Financial ResultsAugust 4, 2025 | globenewswire.comSanuwave Health to Present at Canaccord Genuity Growth ConferenceJuly 22, 2025 | globenewswire.comSanuwave: High Growth Wound Care Tech Primed For A BreakoutJune 11, 2025 | seekingalpha.comSanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial OperationsJune 3, 2025 | globenewswire.comSANUWAVE Health, Inc. (SNWV): A Bull Case TheoryMay 29, 2025 | insidermonkey.comSanuwave Health Appoints Greg Bazar to Board of DirectorsMay 28, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGEN, OPGN, AMRN, and SNWV Company DescriptionsAmarin NASDAQ:AMRN$15.01 +0.04 (+0.27%) Closing price 04:00 PM EasternExtended Trading$14.99 -0.02 (-0.13%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Miragen Therapeutics NASDAQ:MGENMiragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.OpGen NASDAQ:OPGNOpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.Sanuwave Health NASDAQ:SNWV$36.98 -0.04 (-0.11%) As of 04:00 PM EasternSANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
